Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-314: Pirtobrutinib vs Ibrutinib in CLL/SLL
jRCT2021220024Phase 3Recruiting
- Sponsor
- Loxo Oncology
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Loxo Oncology. Primary endpoints: Overall Response Rate (ORR) Part 1 and Overall Response Rate (ORR) Part 2. Started May 2023; status: recruiting.
02
Drugs
pirtobrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2021220024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220024.